

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. RLL-262US	
In Re Application Of: GOGIA et al.						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/518,972		Unknown	26815	Unknown	2913	
Title: PROCESS FOR THE PREPARATION OF ROBUST FORMULATIONS OF VALACYCLOVIR HYDROCHLORIDE TABLETS						
<div style="text-align: center;"> <p>Address to:</p> <p>Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p> </div> <div style="text-align: center; margin-top: 10px;"> <p>37 CFR 1.97(b)</p> </div> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <div style="text-align: center; margin-top: 20px;"> <p>37 CFR 1.97(c)</p> </div> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <div style="margin-left: 40px; margin-top: 10px;"> <p><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center; margin-top: 10px;">OR</p> <p><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p> </div>						

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

RLL-262US

In Re Application: GOGIA et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/518,972		Unknown	26815	Unknown	2913

Title: **PROCESS FOR THE PREPARATION OF ROBUST FORMULATIONS OF VALACYCLOVIR HYDROCHLORIDE TABLETS****Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**Certificate of Transmission by Facsimile***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date) _____

Signature _____

Typed or Printed Name of Person Signing Certificate _____


Certificate of Mailing by ^{Express} First Class MailI hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as ~~first class~~ ^{Express} mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____

(Date) 1/18/2006

Signature of Person Mailing Correspondence _____

Christine Kenedy

Typed or Printed Name of Person Mailing Certificate _____

***This certificate may only be used if paying by deposit account.**
Signature

Dated: January 18, 2006

George E. Heibel

Reg. No. 42,648

CUSTOMER NO. 26815

CC:

P10A/REV05

ALL REFERENCES TO BEST AVAILABLE COPY WHERE LINED THROUGH. /M.M./

INFORMATION DISCLOSURE CITATION

Docket No.: RLL-262US

Serial No.: 10/518,972

Applicants: GIA *et al.*

Filed: 12/21/2004

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/M.M./	A1	4,957,924	9/18/1990	Beauchamp	514	262	
/M.M./	A2	5,879,706	3/9/1999	Carter <i>et al.</i>	424	464	
/M.M./	A3	6,107,302	8/22/200	Carter <i>et al.</i>	514	262	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
/M.M./	B1	WO 96/22082	7/25/1996	PCT	A61K	9/20		
/M.M./	B2	WO 96/22291	7/25/1996	PCT	C07D	473/00		
/M.M./	B3	WO 96/32097	10/17/1996	PCT	A61K	9/20		
/M.M./	B4	WO 97/25989	7/24/1997	PCT	A61K	31/52		
/M.M./	B5	WO 03/022209	3/20/2003	PCT	A61K			
/M.M./	B6	EP 0 308 065	3/22/1989	EPO	C07D	473/18		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Beauchamp <i>et al.</i> , "Amino acid ester prodrugs of acyclovir", <i>Antiviral Chemistry and Chemotherapy</i> , 3(3):157-164 (1992)

EXAMINER /Manu Manohar/ DATE CONSIDERED 08/13/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.